Sumitomo Mitsui Trust Holdings, Inc. Beam Therapeutics Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $168 Billion
- Q3 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 4,830,738 shares of BEAM stock, worth $121 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
4,830,738
Previous 4,729,444
2.14%
Holding current value
$121 Million
Previous $80.4 Million
45.74%
% of portfolio
0.07%
Previous 0.05%
Shares
20 transactions
Others Institutions Holding BEAM
# of Institutions
247Shares Held
95.6MCall Options Held
666KPut Options Held
1.99M-
Farallon Capital Management LLC San Francisco, CA10MShares$250 Million0.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$243 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.85MShares$221 Million1.24% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$191 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.4.73MShares$118 Million0.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.76B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...